Akari Therapeutics, Plc (AKTX) Stock Forecast
AKTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $25.50 average of analyst targets
- Upside to target
- +211.7% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $3.06 – $32.80
AKTX analyst ratings
3 analystsNumber of analysts at each rating.
AKTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AKTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.38 | −$2.38 | −$2.38 | −$1.06 | −125.4% | 1 |
| Current fiscal year (2026) | −$9.05 | −$9.05 | −$9.05 | −$0.01 | −113,025.0% | 1 |
| Next fiscal year (2027) | −$8.65 | −$8.65 | −$8.65 | −$9.05 | +4.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AKTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
AKTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AKTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.00 | −$2.38 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | −$9.05 | — | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$8.65 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AKTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AKTX beat in 5 of 9.
What analysts expect from AKTX
3 analysts cover Akari Therapeutics, Plc; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.50, 211.7% above the latest close of $8.18. Analysts expect earnings of −$9.05 per share for 2026, −113,025.0% from a year earlier. For 2027 the average estimate is −$8.65 per share. Akari Therapeutics, Plc beat the EPS estimate in 5 of the last 9 quarters.
Related: AKTX income statement, AKTX key metrics, AKTX chart. See the AKTX stock overview for the latest quote and news.
AKTX forecast FAQ
What is Akari Therapeutics, Plc's price target?
The average analyst price target for Akari Therapeutics, Plc is $25.50, 211.7% above the latest close of $8.18.
Is Akari Therapeutics, Plc a buy, hold or sell?
Of 3 analysts covering Akari Therapeutics, Plc, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Akari Therapeutics, Plc's EPS forecast?
Analysts forecast −$9.05 per share for 2026 (range −$9.05 to −$9.05); for 2027 the estimate is −$8.65.
When does Akari Therapeutics, Plc report earnings?
Akari Therapeutics, Plc is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Akari Therapeutics, Plc usually beat earnings estimates?
Akari Therapeutics, Plc reported EPS at or above the analyst estimate in 5 of the last 9 quarters.